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74% of the survivors of liver transplantation for alcoholic 
liver disease are able to work and contribute to society as 
a result of having had the transplant procedure. 
Probably the most surprising statistic concerning liver 
transplantation for alcoholic liver disease is the finding that 
89.5% of the transplant survivors have remained alcohol-
abstinent. 12 Of those that have resumed drinking, the 
majority drink only moderately (three or fewer drinks per 
week) as determined by self-report and corroborated by 
their significant other and their primary-care physicians. 
This alcohol abstinence following successful liver trans-
plantation appears to be the rule rather than the exception 
if appropriate selection criteria are utilized for the selection 
of such individuals for transplantation. 
The factors that appear to identify those alcoholics most 
likely to benefit and remain abstinent after successful liver 
transplantation are (I) the support of a significant other. be 
it a spouse, friend. or relative; (2) an acceptance of alcohol 
as the cause for their prior liver disease; (3) active involve-
ment in and completion of a 4- to 6-week alcohol treatment 
program and abstinence for 3 to 6 months prior to trans-
plantation: and (4) an existingjob or an adequate education 
that allows for subsequent employment and. conse-
quently, a redirection of interests away from those asso-
ciated with alcohol use toward other forms of recreation or 
interest. 13-15 
Based on the above experience with liver transplanta-
tion for alcoholic liver disease, it would appear that the 
need for transplantation exists for this group. A high 
survival rate is possible accompanied by a high rate of 
subsequent employment and a surprisingly low rate of 
alcohol abuse recidivism. These facts would appear to 
justify the continued application ofliver transplantation for 
individuals with advanced alcoholic liver disease who, 
without such therapy, would either die or become invalids 
because of their disease. 
VIRAL LIVER DISEASE 
Liver transplantation is a therapeutic option for patients 
with either fulminant hepatic failure or end-stage liver 
disease (cirrhosis) occurring with or without hepatocellular 
cancer due to viral hepatitis (Tables 2 and 3). As was the 
case for alcoholic liver disease, the prevalence of viral 
liver disease is substantial. and the need for some type of 
therapy, be it medical or surgical, is obvious <Table I). 
To date, with the exception of the controversial use of 
prostaglandins in patients with fulminant hepatic failure. 
no specific medical therapy exists, and liver transplanta-
tion is the only realistic therapeutic option currently avail-
able. 16 Compared with historical controls, liver transplan-
tation for individuals with fulminant hepatic failure 
increases the survival rate II-fold. When compared to 
individuals given maximal medical therapy with intent to 
transplant. liver transplantation increases the chance for 
survival threefold. 17 
Fulminant hepatitis attributable to type A or B hepatitis 
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Table 2. Annual Incidence of Viral Hepatitis and Purponed 
Need for Transplantation 
Disease Type 
Type A hepatitis 
Annual incidence 
Fulminant cases 
Type B hepatitiS 
Annual incidence 
Fulminant cases (0.1%) 
Chronic cases (5%) 
Type C hepatitis 
Annual incidence 
Fulminant cases (0.1%) 
Chronic cases (25-50%) 
Cases per 
Year 
1,200,000 
1.200 
300,000 
300 
15,000 
175.000 
175 
43,750 
typically occurs at the two extremes of life. Specifically. in 
children it occurs in those under 10 years of age, and in 
adults it typically occurs in those older than 50. As a result. 
the potential for a long life following recovery from these 
two types offulminant hepatitis is only limited by the older 
age of about half the total cases <the adults older than 50 
years of age). 
Moreover, recurrent disease can occur following liver 
transplantation for fulminant hepatitis due to the A, B, or 
C viruses. 18-20 The data currently available relative to the 
issue of disease recurrence following fulminant type C 
hepatitis as opposed to types A and B have only been 
clinical. but they are nonetheless widely accepted. I- 3 A 
unique complication of both types Band C fulminant 
hepatitis that can occur with either spontaneous recovery 
from the hepatitis or transplantation and that limits long-
term survival is marrow aplasia involving one or more of 
the stem-cell lines present within the marrow. 21 
Worldwide. chronic viral hepatitis leading to decompen-
sated cirrhosis is due either to type B or C hepatitis and is 
the single most frequent indication for liver transplanta-
tion. As was the case with alcoholic liver disease. most of 
the patients with chronic type B hepatitis who are consid-
ered for liver transplantation are in their mid-40s and 
should therefore have the potential for a long life following .. 
successful liver transplantation.2o•22 The major impedi-
Table 3. Indications for LIver Transplantation in Cases of 
Viral Hepatitis 
Type A hepatitiS 
Type B hepatitis 
Type B+D hepatitis 
Type C hepatitiS 
Other NANB hepatitis 
Unusual types (Her-
pes. CMV, EBV, 
adenovirus, and 
others) 
Rare cases of fulminant hepatitiS 
Fulminant and chronic liver dis-
ease 
Hepatoma 
Same as for type B 
Fulminant hepatilis is more likely 
Same as for types A and B 
Similar to type C 
Usually fulminant hepatitis in an 
immunocompromised· host 
r , 
! 
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ment to achieving this goal of a long life following success-
ful transplantation for type B hepatitis (and probably also 
for type C hepatitis) has been the high rate of disease 
recurrence, reported to be almost 100% for those with type 
B hepatitis and as high as 10% to 25% for those with type 
C hepatitis. Preliminary data suggest that the long-term 
survival of transplant recipients with chronic viral hepatitis 
may approach that in patients with other chronic hepato-
cellular diseases with the use of alpha-interferon23 and 
possibly with repeated administrations of either hepatitis B 
immune globulin (HBIG) or one or another of the mono-
clonal antibodies raised against the HBsAg. These agents 
have an activity many orders of magnitude greater than 
that present in commercial lots of HBIG.2o.24-26 Even 
without such therapies. a 50% to 60% survival rate to 5 
years can be expected, despite disease recurrence with 
liver transplantation for chronic viral hepatitis. Thus. it 
would appear that sufficient numbers of patients survive 
and return to a normal. active life to justify the continued 
performance of the procedure.27 .28 With an additional 5 or 
more years of life, those who become reinfected may live 
until an effective antiviral agent can be discovered and 
therefore be made available to treat them without the need 
for retransplantation. The results with such retransplanta-
tions. however, have been less satisfactory than those 
obtained with first grafts for chronic hepatitis. 20 
Based upon the above data. it would appear that sub-
stantial numbers of patients could benefit from liver trans-
plantation for either acute or chronic liver disease. The 
survival rate of such patients may be lower than that 
achieved for other diseases but is sufficiently great to 
justify transplantation. Moreover. the quality of life of 
transplant survivors who were transplanted for viral hep-
atitis is dramatically improved and appears not to be 
significantly different from that of the normal popUlation. 
HEPATIC MALIGNANCY 
Hepatocellular carcinoma (Table 4) is an uncommon. but 
not rare, form of cancer with an annual estimated inci-
dence of 13,600 cases within the United States.29 When 
considering this figure, one has to recognize that the 
United States is a low-incidence area, and more populous 
countries such as China, South Africa. and others have an 
incidence that exceeds 20 cases per 100,000 popUlation, 
making it one of the more frequent types of cancer 
worldwide. The major etiologic factor for hepatic cancer is 
HBV infection, especially early onset or infant/childhood 
disease that occurs as a consequence of vertical transmis-
Table 4. Hepatoblllary Cancer 
Annual incidence: 13,600 cases (US) 
HBV is responsible for 80% of cases worldwide 
HBsAg-positive individuals have a 200- to 300-fold increased risk 
Age at time of infection determines carrier risk 
2:85% if ,,;;10 years 
,,;;10% if 2:20 years 
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sion from mother to child. Hepatoma is also a rather 
common. untoward consequence of chronic liver disease, 
particularly cirrhosis and a number of heritable metabolic 
liver diseases. 
The optimal therapy for hepatocellular carcinoma is 
partial or subtotal hepatectomy. Unfortunately. these pro-
cedures can only be accomplished in individuals with 
normal residual livers and typically those with single 
tumors involving a single hepatic lobe.30.31 Even in the 
best of hands. such surgery carries an operative mortality 
that ranges from 5% to 30%.32 These figures have to be 
counterbalanced by the fact that fewer than 50% of the 
cases explored without intent to transplant are resectable, 
and that fewer than 20% of the cases explored have their 
tumors fully resected. 33 Obviously the only hope for those 
with large tumors involving more than one lobe of the 
liver, those that are located centrally near the porta. those 
that occur in cirrhosis. and those that, until recently, have 
been treated with incomplete tumor removal, is a total 
hepatectomy with liver transplantation. Figure I shows the 
actuarial survival after liver transplantation for hepatitis B 
carriers with and without liver cell cancer compared to that 
of over 1000 individuals transplanted for other causes. It is 
true, as noted earlier, that patients who are HBsAg-
positive at the time of transplantation have a survival rate 
that is reduced by approximately 20% from 2 to 5 years 
after transplantation as compared with all other recipients. 
It can also be seen from this figure that those who have a 
hepatoma and are HBsAg-positive at the time of trans plan-
tation have a 20% reduction in long-term survival from 3 to 
5 years following transplantation. Thus. the presence of a 
hepatoma clearly reduces the long-term prognosis. This is 
not to say that the situation is hopeless. 
When looked at another way, these same data are quite 
hopeful. After 3 years, it seems that 30% of the patients 
transplanted for hepatocellular carcinoma are cured of 
their disease. These cases represent cures in individuals 
who could not be treated with a smaller resection. who are 
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Fig 1. Actuarial survival after liver transplantation tor hepatitis B 
carriers and liver cancer compared to other indications. 
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HBsAg-positive, and who had no hope of survival with 
current modes of chemotherapy, with or without adjuvant 
chemotherapy.34 
It should be noted further that transplant recipients who 
have an incidental tumor, that is, one whose largest 
diameter is less than 5 em and typically is encapsulated and 
shows no evidence for vascular invasion upon histologic 
examination of the resected specimen, can be cured with a 
90% survival rate at 3 years or more after transplantation. 
As expected, the removal of such cases from the larger 
group of all cases transplanted for hepatocellular carci-
noma reduces the rate of success achieved in the remaining 
cases. The data available from Europe appear to corrobo-
rate the data available from Pittsburgh concerning these 
issues. 8•35 
The reported experience with fibrolamellar carcino-
ma36-38 and epithelial hemangioendothelioma39-41 is some-
what better than that observed with other types of hepatic 
cancer. Conversely, the prognosis with cholangiolar car-
cinoma has been considerably worse.5•9•42 
The improvements that may occur with the addition of 
adjuvant chemotherapy, immunotherapy, and an aggres-
sive attack upon micro metastasis identified during the 
anhepatic phase of the procedure using radiolabelled 
monoclonal antibodies directed at oncofetal hepatocyte 
surface antigens remain to be determined, but they are 
expected. to improve current results. 
Thus, the fact that (1) transplantation can cure as many 
as 25% to 30% of patients that would otherwise die without 
transplantation; that (2) disease-free intervals of 2 to 3 
years can be achieved, providing those destined to expe-
rience disease recurrence an extension of high-quality life; 
and that (3) no competitive medical or radiotherapy op-
tions currently exist, suggest rather strongly that liver 
transplantation ought to be and will continue to be offered 
to individuals with hepatocellular carcinoma. The data also 
suggest that as techniques for cancer surveillance such as 
quarterly alpha-fetoprotein and descarboxyprothrombin 
and semiannual ultrasound examinations become routine, 
more hepatic cancers will be identified while they are 
"incidental" lesions, when the prognosis with liver trans-
plantation is markedly improved. As a result. the overall 
prognosis of individuals transplanted for hepatic cancer 
should improve remarkably. 
SUMMARY 
In closing, it is important to note that the indications for 
liver transt>lantation are not static but rather are remark-
ably dynamic and capable of change over time. Thus 
yesterday's major indications can become relative con-
traindications, while yesterday's absolute contraindica-
tions have become today's nuisances. The goal for physi-
cians who care for individuals with problems such as 
alcoholic liver disease, viral hepatitis, and hepatic cancer 
should be to develop new strategies of care that will 
ultimately eliminate these diseases as problems, rather 
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than eliminating individuals with such health problems 
from currently available health options. In other words, 
physicians who accept the responsibility for a patient's life 
should be searching for the best form of therapy available 
for their patient rather than examining the reasons that 
exist for limiting one's choice in health care. 
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